Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This single center phase 1 trial will study the combination of nivolumab+ipilimumab with
embolization in participants with renal cell carcinoma. The study will evaluate the safety of
embolotherapy in patients with metastatic RCC receiving nivolumab+ipilimumab. The hypothesis
is that the number of serious adverse events will be no greater than the number of serious
adverse events for both therapies combined.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania University of Pennsylvania